Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares insights on the long-term overall survival benefit demonstrated by neoadjuvant nivolumab plus chemotherapy among patients with resectable non-small cell lung cancer, as seen in the CheckMate 816 trial.
Patrick Forde, MBBCh, shares...